Follow
Stephen Pettitt
Stephen Pettitt
Verified email at icr.ac.uk
Title
Cited by
Cited by
Year
The shieldin complex mediates 53BP1-dependent DNA repair
SM Noordermeer, S Adam, D Setiaputra, M Barazas, SJ Pettitt, AK Ling, ...
Nature 560 (7716), 117-121, 2018
5252018
Agouti C57BL/6N embryonic stem cells for mouse genetic resources
SJ Pettitt, Q Liang, XY Rairdan, JL Moran, HM Prosser, DR Beier, ...
Nature methods 6 (7), 493-495, 2009
4232009
Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance
SJ Pettitt, DB Krastev, I Brandsma, A Dréan, F Song, R Aleksandrov, ...
Nature communications 9 (1), 1849, 2018
3522018
PARP inhibition enhances tumor cell–intrinsic immunity in ERCC1-deficient non–small cell lung cancer
RM Chabanon, G Muirhead, DB Krastev, J Adam, D Morel, M Garrido, ...
The Journal of clinical investigation 129 (3), 1211-1228, 2019
2622019
Structural basis for allosteric PARP-1 retention on DNA breaks
L Zandarashvili, MF Langelier, UK Velagapudi, MA Hancock, JD Steffen, ...
Science 368 (6486), eaax6367, 2020
2092020
A genetic screen using the PiggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicity
SJ Pettitt, FL Rehman, I Bajrami, R Brough, F Wallberg, I Kozarewa, ...
PloS one 8 (4), e61520, 2013
1812013
Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance
D Zatreanu, HMR Robinson, O Alkhatib, M Boursier, H Finch, L Geo, ...
Nature communications 12 (1), 3636, 2021
1742021
Phase I trial of first-in-class ATR inhibitor M6620 (VX-970) as monotherapy or in combination with carboplatin in patients with advanced solid tumors
TA Yap, B O’Carrigan, MS Penney, JS Lim, JS Brown, ...
Journal of Clinical Oncology 38 (27), 3195, 2020
1742020
The CST complex mediates end protection at double-strand breaks and promotes PARP inhibitor sensitivity in BRCA1-deficient cells
M Barazas, S Annunziato, SJ Pettitt, I de Krijger, H Ghezraoui, SJ Roobol, ...
Cell reports 23 (7), 2107-2118, 2018
1312018
Clinical BRCA1/2 Reversion Analysis Identifies Hotspot Mutations and Predicted Neoantigens Associated with Therapy Resistance
SJ Pettitt, JR Frankum, M Punta, S Lise, J Alexander, Y Chen, TA Yap, ...
Cancer discovery 10 (10), 1475-1488, 2020
1062020
Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells
J Nikkilä, R Kumar, J Campbell, I Brandsma, HN Pemberton, F Wallberg, ...
British journal of cancer 117 (1), 113-123, 2017
1052017
E-cadherin/ROS1 inhibitor synthetic lethality in breast cancer
I Bajrami, R Marlow, M van de Ven, R Brough, HN Pemberton, J Frankum, ...
Cancer discovery 8 (4), 498-515, 2018
952018
The piggyBac Transposon Displays Local and Distant Reintegration Preferences and Can Cause Mutations at Noncanonical Integration Sites
MA Li, SJ Pettitt, S Eckert, Z Ning, S Rice, J Cadiñanos, K Yusa, N Conte, ...
Molecular and cellular biology 33 (7), 1317-1330, 2013
952013
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non–BRCA1/2-Mutant Cancers
TA Yap, R Kristeleit, V Michalarea, SJ Pettitt, JSJ Lim, S Carreira, D Roda, ...
Cancer discovery 10 (10), 1528-1543, 2020
872020
Biomarkers associating with PARP inhibitor benefit in prostate cancer in the TOPARP-B trial
S Carreira, N Porta, S Arce-Gallego, G Seed, A Llop-Guevara, D Bianchini, ...
Cancer discovery 11 (11), 2812-2827, 2021
832021
HNF4A and GATA6 loss reveals therapeutically actionable subtypes in pancreatic cancer
H Brunton, G Caligiuri, R Cunningham, R Upstill-Goddard, UM Bailey, ...
Cell reports 31 (6), 2020
802020
Defective ALC1 nucleosome remodeling confers PARPi sensitization and synthetic lethality with HRD
G Hewitt, V Borel, S Segura-Bayona, T Takaki, P Ruis, R Bellelli, ...
Molecular cell 81 (4), 767-783. e11, 2021
772021
The ubiquitin-dependent ATPase p97 removes cytotoxic trapped PARP1 from chromatin
DB Krastev, S Li, Y Sun, AJ Wicks, G Hoslett, D Weekes, LM Badder, ...
Nature cell biology 24 (1), 62-73, 2022
712022
PBRM1 deficiency confers synthetic lethality to DNA repair inhibitors in cancer
RM Chabanon, D Morel, T Eychenne, L Colmet-Daage, I Bajrami, ...
Cancer research 81 (11), 2888-2902, 2021
672021
Modeling Therapy Resistance in BRCA1/2-Mutant Cancers
A Dréan, CT Williamson, R Brough, I Brandsma, M Menon, A Konde, ...
Molecular cancer therapeutics 16 (9), 2022-2034, 2017
662017
The system can't perform the operation now. Try again later.
Articles 1–20